['CONCOMITANT DRUG CLASS: DRUG NAME', 'EFFECT ON CONCENTRATION OF DELAVIRDINE OR CONCOMITANT DRUG', 'CLINICAL COMMENT', 'HIV-ANTIVIRAL AGENTS: NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR', 'DIDANOSINE A', '\xe2\x86\x93DELAVIRDINE \xe2\x86\x93DIDANOSINE', 'ADMINISTRATION OF DIDANOSINE (BUFFERED TABLETS) AND RESCRIPTOR SHOULD BE SEPARATED BY AT LEAST 1\xc2\xa0HOUR.', 'HIV-ANTIVIRAL AGENTS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS', 'NNRTI', '\xe2\x86\x94DELAVIRDINE \xe2\x86\x91NNRTI', 'COMBINING NNRTIS HAS NOT BEEN SHOWN TO BE BENEFICIAL. RESCRIPTOR SHOULD NOT BE COADMINISTERED WITH ANOTHER NNRTI.', 'HIV-ANTIVIRAL AGENTS: PROTEASE INHIBITORS', 'INDINAVIR A', '\xe2\x86\x91INDINAVIR', 'A DOSE REDUCTION OF INDINAVIR TO 600 MG 3\xc2\xa0TIMES DAILY SHOULD BE CONSIDERED WHEN RESCRIPTOR AND INDINAVIR ARE COADMINISTERED.', 'LOPINAVIR/RITONAVIR', '\xe2\x86\x91LOPINAVIR \xe2\x86\x91RITONAVIR', 'APPROPRIATE DOSES OF THIS COMBINATION WITH RESPECT TO SAFETY, EFFICACY, AND PHARMACOKINETICS HAVE NOT BEEN ESTABLISHED.', 'NELFINAVIR A', '\xe2\x86\x91NELFINAVIR \xe2\x86\x93DELAVIRDINE', 'APPROPRIATE DOSES OF THIS COMBINATION WITH RESPECT TO SAFETY, EFFICACY, AND PHARMACOKINETICS HAVE NOT BEEN ESTABLISHED (SEE CLINICAL PHARMACOLOGY: TABLES 1 AND 2).', 'RITONAVIR', '\xe2\x86\x91RITONAVIR', 'APPROPRIATE DOSES OF THIS COMBINATION WITH RESPECT TO SAFETY, EFFICACY, AND PHARMACOKINETICS HAVE NOT BEEN ESTABLISHED.', 'SAQUINAVIR A', '\xe2\x86\x91SAQUINAVIR', 'A DOSE REDUCTION OF SAQUINAVIR (SOFT GELATIN CAPSULES) MAY BE CONSIDERED WHEN RESCRIPTOR AND SAQUINAVIR ARE COADMINISTERED (SEE CLINICAL PHARMACOLOGY: TABLE 1). APPROPRIATE DOSES WITH RESPECT TO SAFETY, EFFICACY, AND PHARMACOKINETICS HAVE NOT BEEN ESTABLISHED.', 'HIV-ANTIVIRAL AGENTS: CCR5 INHIBITOR', 'MARAVIROC', '\xe2\x86\x91MARAVIROC', 'CONCOMITANT USE OF RESCRIPTOR AND MARAVIROC HAS NOT BEEN STUDIED. HOWEVER, RESCRIPTOR IS A POTENT CYP3A4 INHIBITOR AND THE MARAVIROC DOSE SHOULD BE REDUCED DURING COADMINISTRATION. REFER TO THE FULL PRESCRIBING INFORMATION FOR MARAVIROC (SELZENTRY) FOR DOSING RECOMMENDATIONS.', 'OTHER AGENTS', 'ACID BLOCKERS: ANTACIDS A', '\xe2\x86\x93DELAVIRDINE', 'DOSES OF AN ANTACID AND RESCRIPTOR SHOULD BE SEPARATED BY AT LEAST 1\xc2\xa0HOUR, BECAUSE THE ABSORPTION OF DELAVIRDINE IS REDUCED WHEN COADMINISTERED WITH ANTACIDS.', 'HISTAMINE H 2 -RECEPTOR ANTAGONISTS: CIMETIDINE, FAMOTIDINE, NIZATIDINE, RANITIDINE', '\xe2\x86\x93DELAVIRDINE', 'THESE AGENTS INCREASE GASTRIC PH AND MAY REDUCE THE ABSORPTION OF DELAVIRDINE. ALTHOUGH THE EFFECT OF THESE DRUGS ON DELAVIRDINE ABSORPTION HAS NOT BEEN EVALUATED, CHRONIC USE OF THESE DRUGS WITH RESCRIPTOR IS NOT RECOMMENDED.', 'PROTON PUMP INHIBITORS: OMEPRAZOLE, LANSOPRAZOLE', '\xe2\x86\x93DELAVIRDINE', 'THESE AGENTS INCREASE GASTRIC PH AND MAY REDUCE THE ABSORPTION OF DELAVIRDINE. ALTHOUGH THE EFFECT OF THESE DRUGS ON DELAVIRDINE ABSORPTION HAS NOT BEEN EVALUATED, CHRONIC USE OF THESE DRUGS WITH RESCRIPTOR IS NOT RECOMMENDED.', 'AMPHETAMINES', '\xe2\x86\x91AMPHETAMINES', 'USE WITH CAUTION.', 'ANTIDEPRESSANT: TRAZODONE', '\xe2\x86\x91TRAZODONE', 'CONCOMITANT USE OF TRAZODONE AND RESCRIPTOR MAY INCREASE PLASMA CONCENTRATIONS OF TRAZODONE. ADVERSE EVENTS OF NAUSEA, DIZZINESS, HYPOTENSION, AND SYNCOPE HAVE BEEN OBSERVED FOLLOWING COADMINISTRATION OF TRAZODONE AND RITONAVIR. IF TRAZODONE IS USED WITH A CYP3A4 INHIBITOR SUCH AS RESCRIPTOR, THE COMBINATION SHOULD BE USED WITH CAUTION AND A LOWER DOSE OF TRAZODONE SHOULD BE CONSIDERED.', 'ANTIARRHYTHMICS: BEPRIDIL', '\xe2\x86\x91ANTIARRHYTHMICS', 'USE WITH CAUTION. INCREASED BEPRIDIL EXPOSURE MAY BE ASSOCIATED WITH LIFE\xe2\x80\x91THREATENING REACTIONS SUCH AS CARDIAC ARRHYTHMIAS.', 'AMIODARONE, LIDOCAINE (SYSTEMIC), QUINIDINE, FLECAINIDE, PROPAFENONE', '', 'CAUTION IS WARRANTED AND THERAPEUTIC CONCENTRATION MONITORING IS RECOMMENDED, IF AVAILABLE, FOR ANTIARRHYTHMICS WHEN COADMINISTERED WITH RESCRIPTOR.', 'ANTICOAGULANT: WARFARIN', '\xe2\x86\x91WARFARIN', 'IT IS RECOMMENDED THAT INR (INTERNATIONAL NORMALIZED RATIO) BE MONITORED.', 'ANTI-INFECTIVE: CLARITHROMYCIN A', '\xe2\x86\x91CLARITHROMYCIN', 'WHEN COADMINISTERED WITH RESCRIPTOR, CLARITHROMYCIN SHOULD BE ADJUSTED IN PATIENTS WITH IMPAIRED RENAL FUNCTION:', 'CALCIUM CHANNEL BLOCKERS: AMLODIPINE, DILTIAZEM, FELODIPINE, ISRADIPINE, NIFEDIPINE, NICARDIPINE, NIMODIPINE, NISOLDIPINE, VERAPAMIL', '\xe2\x86\x91CALCIUM CHANNEL BLOCKERS', 'CAUTION IS WARRANTED AND CLINICAL MONITORING OF PATIENTS IS RECOMMENDED.', 'CORTICOSTEROID: DEXAMETHASONE', '\xe2\x86\x93DELAVIRDINE', 'USE WITH CAUTION. RESCRIPTOR MAY BE LESS EFFECTIVE DUE TO DECREASED DELAVIRDINE PLASMA CONCENTRATIONS IN PATIENTS TAKING THESE AGENTS CONCOMITANTLY.', 'ERECTILE DYSFUNCTION AGENTS: SILDENAFIL', '\xe2\x86\x91SILDENAFIL', 'SILDENAFIL SHOULD NOT EXCEED A MAXIMUM SINGLE DOSE OF 25\xc2\xa0MG IN A 48\xe2\x80\x91HOUR PERIOD.', 'HMG-COA REDUCTASE INHIBITORS: ATORVASTATIN, CERIVASTATIN, FLUVASTATIN', '\xe2\x86\x91ATORVASTATIN \xe2\x86\x91CERIVASTATIN \xe2\x86\x91FLUVASTATIN', 'USE LOWEST POSSIBLE DOSE OF ATORVASTATIN OR CERIVASTATIN, OR FLUVASTATIN WITH CAREFUL MONITORING, OR CONSIDER OTHER HMG-COA REDUCTASE INHIBITORS SUCH AS PRAVASTATIN IN COMBINATION WITH RESCRIPTOR.', 'IMMUNOSUPPRESSANTS: CYCLOSPORINE, TACROLIMUS, RAPAMYCIN', '\xe2\x86\x91IMMUNOSUPPRESSANTS', 'THERAPEUTIC CONCENTRATION MONITORING IS RECOMMENDED FOR IMMUNOSUPPRESSANT AGENTS WHEN COADMINISTERED WITH RESCRIPTOR.', 'INHALED/NASAL STEROID: FLUTICASONE', '\xe2\x86\x91FLUTICASONE', 'CONCOMITANT USE OF FLUTICASONE AND RESCRIPTOR MAY INCREASE PLASMA CONCENTRATIONS OF FLUTICASONE. USE WITH CAUTION. CONSIDER ALTERNATIVES TO FLUTICASONE, PARTICULARLY FOR LONG-TERM USE.', 'NARCOTIC ANALGESIC: METHADONE', '\xe2\x86\x91METHADONE', 'DOSAGE OF METHADONE MAY NEED TO BE DECREASED WHEN COADMINISTERED WITH RESCRIPTOR.', 'ORAL CONTRACEPTIVES: ETHINYL ESTRADIOL', '\xe2\x86\x91ETHINYL ESTRADIOL', 'CONCENTRATIONS OF ETHINYL ESTRADIOL MAY INCREASE. HOWEVER, THE CLINICAL SIGNIFICANCE IS UNKNOWN.']